Last reviewed · How we verify
MEDI-563
At a glance
| Generic name | MEDI-563 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Pharyngitis
- Hypersensitivity reactions
- Pyrexia
- Injection site reactions
Key clinical trials
- A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases (PHASE3)
- This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (PHASE4)
- Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
- A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) (PHASE3)
- Fasenra Pediatric Japan Post-Marketing Study(PMS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI-563 CI brief — competitive landscape report
- MEDI-563 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI